Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide’s Broader Metabolic Data

Altimmune, Inc. (NASDAQ:ALT) is one of the small-cap stocks with potential to rise 1000 percent. The company’s lead drug candidate, pemvidutide, is being developed for MASH, a serious liver disease tied to fat buildup, inflammation, and scarring in the liver. On May 28, Altimmune said new 48-week data from its IMPACT Phase 2b study showed improvements in several health measures linked to MASH, including triglycerides, cholesterol, body weight, waist size, and blood pressure. At the 1.8 mg dose, patients with elevated baseline levels saw triglycerides fall 23.7% and total cholesterol fall 15.4% versus placebo.

Altimmune is trying to move pemvidutide into a larger Phase 3 study rather than leaving the program at mid-stage data. In its May 13 first-quarter update, the company said it expects to start the PERFORMA Phase 3 MASH trial in the second half of 2026, with 52-week data expected in 2029. The company is also testing pemvidutide in alcohol use disorder and alcohol-associated liver disease, with data or enrollment updates expected later in 2026. Altimmune had about $535 million in cash, cash equivalents, and short-term investments as of April 30, 2026, giving it a stronger balance sheet as the program moves into larger trials.

Altimmune, Inc. (NASDAQ:ALT) is a late clinical-stage biotechnology company developing pemvidutide for serious liver diseases, including MASH, alcohol use disorder, and alcohol-associated liver disease.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.